These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 32092187)
1. Preliminary assessment of safety and adherence to a once-daily immunosuppression regimen in kidney transplantation: Results of a randomized controlled pilot study. Taber DJ; Posadas-Salas A; Su Z; Rao V; Rohan V; Nadig S; McGillicuddy JW; Dubay D; Fleming JN Clin Transplant; 2020 Apr; 34(4):e13844. PubMed ID: 32092187 [TBL] [Abstract][Full Text] [Related]
2. Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP-Tacrolimus. Taber DJ; Bartlett F; Patel N; Sprague T; Patel S; Newman J; Andrade E; Rao N; Salas MAP; Casey M; Dubay D; Rohan V Clin Transplant; 2023 May; 37(5):e14941. PubMed ID: 36809653 [TBL] [Abstract][Full Text] [Related]
3. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation. Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870 [TBL] [Abstract][Full Text] [Related]
4. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center. Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936 [TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial assessing the impact of everolimus and low-exposure tacrolimus on graft outcomes in kidney transplant recipients. Taber DJ; Chokkalingam A; Su Z; Self S; Miller D; Srinivas T Clin Transplant; 2019 Oct; 33(10):e13679. PubMed ID: 31365151 [TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study. Lee EC; Kim SH; Park SJ Ann Transplant; 2018 Oct; 23():713-720. PubMed ID: 30310047 [TBL] [Abstract][Full Text] [Related]
7. Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial. Okumi M; Unagami K; Furusawa M; Kakuta Y; IIzuka J; Takagi T; Shirakawa H; Shimizu T; Omoto K; Inui M; Ishida H; Tanabe K Clin Transplant; 2018 Dec; 32(12):e13423. PubMed ID: 30318624 [TBL] [Abstract][Full Text] [Related]
8. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K; Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860 [TBL] [Abstract][Full Text] [Related]
9. Improvement of medication adherence with simplified once-daily immunosuppressive regimen in stable kidney transplant recipients: A prospective cohort study. Oh CK; Bang JB; Kim SJ; Huh KH; Kim SJ; Jeon JS; Han SY; Cho HR; Kwon YJ; Lee SH; Kim YS Asian J Surg; 2020 Jun; 43(6):660-667. PubMed ID: 31353239 [TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Höcker B; Tönshoff B Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600 [TBL] [Abstract][Full Text] [Related]
11. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629 [TBL] [Abstract][Full Text] [Related]
12. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients. Kim SH; Lee SD; Kim YK; Park SJ Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081 [TBL] [Abstract][Full Text] [Related]